ZA202306172B - Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase - Google Patents

Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase

Info

Publication number
ZA202306172B
ZA202306172B ZA2023/06172A ZA202306172A ZA202306172B ZA 202306172 B ZA202306172 B ZA 202306172B ZA 2023/06172 A ZA2023/06172 A ZA 2023/06172A ZA 202306172 A ZA202306172 A ZA 202306172A ZA 202306172 B ZA202306172 B ZA 202306172B
Authority
ZA
South Africa
Prior art keywords
bruton
benzoazepine
analogs
tyrosine kinase
inhibiting agents
Prior art date
Application number
ZA2023/06172A
Other languages
English (en)
Inventor
Brian T Hopkins
Bin Ma
Robin Prince
Isaac Marx
Joseph P Lyssikatos
Fengmei Zheng
Matthew Peterson
Daniel B Patience
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of ZA202306172B publication Critical patent/ZA202306172B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2023/06172A 2017-04-14 2023-06-12 Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase ZA202306172B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762485745P 2017-04-14 2017-04-14

Publications (1)

Publication Number Publication Date
ZA202306172B true ZA202306172B (en) 2024-11-27

Family

ID=62092333

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/06172A ZA202306172B (en) 2017-04-14 2023-06-12 Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase

Country Status (36)

Country Link
US (5) US10227341B2 (cg-RX-API-DMAC7.html)
EP (2) EP4249071A3 (cg-RX-API-DMAC7.html)
JP (3) JP7145874B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250140646A (cg-RX-API-DMAC7.html)
CN (2) CN117567453A (cg-RX-API-DMAC7.html)
AR (2) AR111594A1 (cg-RX-API-DMAC7.html)
AU (3) AU2018253209B2 (cg-RX-API-DMAC7.html)
CA (1) CA3058774A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002900A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012571A2 (cg-RX-API-DMAC7.html)
CR (2) CR20190517A (cg-RX-API-DMAC7.html)
DK (1) DK3609886T3 (cg-RX-API-DMAC7.html)
EA (1) EA201992354A1 (cg-RX-API-DMAC7.html)
ES (1) ES2975769T3 (cg-RX-API-DMAC7.html)
FI (1) FI3609886T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240361T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066253T2 (cg-RX-API-DMAC7.html)
IL (3) IL269933B (cg-RX-API-DMAC7.html)
JO (1) JOP20190233B1 (cg-RX-API-DMAC7.html)
LT (1) LT3609886T (cg-RX-API-DMAC7.html)
MA (1) MA50013B1 (cg-RX-API-DMAC7.html)
MD (1) MD3609886T2 (cg-RX-API-DMAC7.html)
MX (1) MX2023000812A (cg-RX-API-DMAC7.html)
PE (2) PE20240930A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502334A1 (cg-RX-API-DMAC7.html)
PL (1) PL3609886T3 (cg-RX-API-DMAC7.html)
PT (1) PT3609886T (cg-RX-API-DMAC7.html)
RS (1) RS65386B1 (cg-RX-API-DMAC7.html)
SA (1) SA519410292B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201909224QA (cg-RX-API-DMAC7.html)
SI (1) SI3609886T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400166T1 (cg-RX-API-DMAC7.html)
TW (2) TWI846229B (cg-RX-API-DMAC7.html)
UA (1) UA127347C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018191577A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306172B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
RS65386B1 (sr) 2017-04-14 2024-04-30 Biogen Ma Inc Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze
US11820760B2 (en) 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
JP7747523B2 (ja) * 2019-05-15 2025-10-01 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240216330A1 (en) * 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023086521A1 (en) 2021-11-10 2023-05-19 Biogen Ma Inc. Btk inhibitors
CA3240051A1 (en) 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
ES2406129T3 (es) 2007-10-05 2013-06-05 Verastem, Inc. Derivados de purina sustituidos con pirimidina
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI557127B (zh) * 2009-09-04 2016-11-11 百健Ma公司 布魯頓氏酪胺酸激酶抑制劑
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
TWI648274B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
CN107001362A (zh) 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
RS65386B1 (sr) 2017-04-14 2024-04-30 Biogen Ma Inc Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze

Also Published As

Publication number Publication date
IL316713A (en) 2024-12-01
PE20240930A1 (es) 2024-04-30
EA201992354A1 (ru) 2020-03-10
CA3058774A1 (en) 2018-10-18
JP2022180498A (ja) 2022-12-06
CL2019002900A1 (es) 2020-01-24
US20180362522A1 (en) 2018-12-20
EP3609886B1 (en) 2024-02-07
US20210340135A1 (en) 2021-11-04
TW201841909A (zh) 2018-12-01
JOP20190233A1 (ar) 2019-10-02
JP2025020247A (ja) 2025-02-12
US11427577B2 (en) 2022-08-30
PT3609886T (pt) 2024-04-11
MD3609886T2 (ro) 2024-07-31
US10227341B2 (en) 2019-03-12
HUE066253T2 (hu) 2024-07-28
UA127347C2 (uk) 2023-07-26
CN117567453A (zh) 2024-02-20
CN110621670A (zh) 2019-12-27
PL3609886T3 (pl) 2024-05-13
KR20250140646A (ko) 2025-09-25
AR111594A1 (es) 2019-07-31
BR112019021399A2 (pt) 2020-04-28
JP2020516659A (ja) 2020-06-11
MX2023000812A (es) 2023-02-27
IL294175B2 (en) 2025-04-01
TWI846229B (zh) 2024-06-21
KR102862996B1 (ko) 2025-09-22
KR102607900B1 (ko) 2023-11-29
DK3609886T3 (da) 2024-03-18
SMT202400166T1 (it) 2024-07-09
AU2018253209B2 (en) 2022-06-02
KR20190139926A (ko) 2019-12-18
JP7778206B2 (ja) 2025-12-01
TW202315870A (zh) 2023-04-16
PH12019502334A1 (en) 2020-09-21
PE20200740A1 (es) 2020-07-24
AU2018253209A1 (en) 2019-10-31
TWI790227B (zh) 2023-01-21
IL269933A (cg-RX-API-DMAC7.html) 2019-11-28
CR20230539A (es) 2024-04-08
US10961237B2 (en) 2021-03-30
SI3609886T1 (sl) 2024-05-31
HRP20240361T1 (hr) 2024-06-07
IL294175A (en) 2022-08-01
JP7581294B2 (ja) 2024-11-12
IL269933B (en) 2022-07-01
SG11201909224QA (en) 2019-11-28
NZ757929A (en) 2025-10-31
MA50013A (fr) 2020-07-08
CR20190517A (es) 2020-02-13
IL294175B1 (en) 2024-12-01
LT3609886T (lt) 2024-04-10
JP7145874B2 (ja) 2022-10-03
US10189829B2 (en) 2019-01-29
JOP20190233B1 (ar) 2024-04-18
EP4249071A2 (en) 2023-09-27
US11858926B2 (en) 2024-01-02
AU2022218560A1 (en) 2022-09-15
RS65386B1 (sr) 2024-04-30
ES2975769T3 (es) 2024-07-15
CO2019012571A2 (es) 2020-01-17
EP4249071A3 (en) 2024-01-24
KR20230164247A (ko) 2023-12-01
AU2024204241A1 (en) 2024-07-11
SA519410292B1 (ar) 2023-03-12
EP3609886A1 (en) 2020-02-19
FI3609886T3 (fi) 2024-03-26
US20200239459A1 (en) 2020-07-30
CN110621670B (zh) 2023-09-15
WO2018191577A1 (en) 2018-10-18
AR129632A2 (es) 2024-09-11
AU2022218560B2 (en) 2024-04-04
MA50013B1 (fr) 2024-05-31
US20230147490A1 (en) 2023-05-11
US20180297992A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
PH12016500531A1 (en) Compound inhibiting activities of btk and/or jak3 kinases
PH12018502427A1 (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
MY192354A (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
GEP201706748B (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
PH12019502601A1 (en) Therapeutic compounds and compositions, and methods of use thereof
TN2017000158A1 (en) Carbazole derivatives
PH12016502353A1 (en) Pharmaceutical composition
WO2016109217A3 (en) Btk inhibitors
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
TW201613577A (en) Pharmaceutical combinations
SG10201903621SA (en) Tricyclic atropisomer compounds
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
MX2020009334A (es) Compuestos para tratar la enfermedad de alzheimer.
WO2020232330A8 (en) Inhibiting agents for bruton's tyrosine kinase
MX2021001783A (es) Agentes inhibidores de ask1.
HK1233259A1 (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer